Lipid metabolic reprogramming in immune regulation and chronic inflammatory diseases
Endocrine Journal · 2025 · 72 (9) · 979-985
DOI: 10.1507/endocrj.ej25-0180 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine Journal, 2025. Verfasst von Ayaka Ito. Beteiligte Einrichtung: Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan. Hauptthemen laut MEDLINE: Lipid Metabolism, Inflammation, Autoimmune Diseases, Immune System. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science, Fusion Oriented REsearch for disruptive Science and Technology, Takeda Science Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
- Department of Immunometabolism, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Institute for Advanced Research, Nagoya University, Nagoya, Japan.
Förderung
- Japan Society for the Promotion of Science
- Fusion Oriented REsearch for disruptive Science and Technology
- Takeda Science Foundation
- Inamori Foundation
- Lotte Foundation
Zitieren
APA
Ito, A. (2025). Lipid metabolic reprogramming in immune regulation and chronic inflammatory diseases. Endocrine Journal, 72(9), 979-985. https://doi.org/10.1507/endocrj.ej25-0180
Vancouver
Ito A. Lipid metabolic reprogramming in immune regulation and chronic inflammatory diseases. Endocrine Journal. 2025;72(9):979-985. doi:10.1507/endocrj.ej25-0180
BibTeX
@article{Ito2025,
author = {Ito, Ayaka},
title = {Lipid metabolic reprogramming in immune regulation and chronic inflammatory diseases},
journal = {Endocrine Journal},
year = {2025},
volume = {72},
number = {9},
pages = {979--985},
doi = {10.1507/endocrj.ej25-0180}
}
EUVIMED